David Griffith is senior vice president of non-clinical and clinical development with more than 30 years of experience in drug discovery and development.
Prior to joining Qpex, David led teams responsible for non-clinical and clinical pharmacology, toxicology, chemistry, manufacturing and controls at Mpex Pharmaceuticals, Rempex Pharmaceuticals, Inc. and The Medicines Company. His work supported multiple Investigational New Drug Applications, which resulted in regulatory approvals for MINOCIN® (minocycline) for Injection and VABOMERE™ (meropenem and vaborbactam) as well as investigational medicinal product dossiers, which resulted in regulatory approvals for QUINSAIR® (levofloxacin nebuliser solution). David has extensive experience in the determination and application of the pharmacokinetics and pharmacodynamics of antibacterial agents from discovery to approval. Prior to Mpex, David held positions of increasing responsibility overseeing clinical and non-clinical pharmacology, drug product and formulation development, and manufacturing at CovX Research LLC and Microcide Pharmaceuticals. He is an inventor with 32 issued patents and has authored more than 50 original research papers.
David earned a Bachelor of Arts in biology from the University of California at Santa Cruz, Santa Cruz, California.
